- Conditions
- Spinal Cord Injuries
- Interventions
- Testosterone Undecanoate, hybrid exercise
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 100
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Insulin Resistance, Postmenopause
- Interventions
- metformin, leuprolide injection, placebo pill, placebo injection
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years to 79 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metabolic Syndrome
- Interventions
- intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- ganirelix acetate, methyl testosterone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Polycystic Ovary Syndrome, Obstructive Sleep Apnea
- Interventions
- continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
- Device · Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Testosterone injection, Testosterone gel, Testosterone Oral
- Drug
- Lead sponsor
- Sports Medicine Research and Testing Laboratory
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- South Jordan, Utah
- Conditions
- Healthy
- Interventions
- Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypogonadotropic Hypogonadism, Type 2 Diabetes
- Interventions
- testosterone, clomiphene, placebo
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Contraception, Hypogonadism
- Interventions
- Oral Testosterone, Leuprolide (Lupron), Dutasteride
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Leuprolide
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 59
- States / cities
- Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more
- Conditions
- Sarcopenia
- Interventions
- Testosterone enanthate, Placebo
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 60 Years to 75 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- Testosterone cypionate, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
- Interventions
- testosterone cypionate, finasteride, placebo injection, placebo pill
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
- Conditions
- Testosterone Deficiency, Hypogonadism, Male
- Interventions
- Testosterone
- Drug
- Lead sponsor
- Men's Health Boston
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Interventions
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Diagnostic Test · Drug · Radiation
- Lead sponsor
- Martin T. King, MD, PhD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
- Conditions
- Prostate Cancer Adenocarcinoma in Situ
- Interventions
- degarelix acetate, Cyclophosphamide, GVAX
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide acetate 22.5 mg depot, GP-Pharm SA
- Drug
- Lead sponsor
- GP-Pharm
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 25
- States / cities
- San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
- Conditions
- Hypogonadism, Hypogonadism, Male, Hypogonadotropic Hypogonadism
- Interventions
- Aveed Injectable Product, Fortesta, Testim
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 27 more
- Conditions
- Transgenderism, Reproductive Issues
- Interventions
- Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Mobility Limitation
- Interventions
- Testosterone enanthate
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate 200 Mg/ML, Intranasal Testosterone
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida